Ivitinib debuts at 2019 ASCO Annual Meeting

From May 31 to June 4, 2019, the 55th American Society of Clinical Oncology (ASCO) Annual Meeting kicked off in Chicago, USA.

On the morning of June 2, local time, China's first third-generation EGFR-TKI abivertinib, independently developed by Hangzhou Aisen Pharmaceutical Research Co., Ltd., was unveiled at the 2019 ASCO Annual Meeting and demonstrated its clinical research results in the treatment of Chinese EGFR-T790M mutation-positive non-small cell lung cancer patients—Safety and efficacy of abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in Chinese patients with EGFR-T790M positive non-small cell lung cancer. This is also the second time that Avitinib has appeared at the ASCO annual meeting.

The leader unit responsible for this clinical study is the clinical team of Guangdong Provincial People's Hospital led by Professor Wu Yilong. 17 participating clinical centers include Hunan Cancer Hospital, West China Hospital of Sichuan University, Beijing Cancer Hospital, and the First Affiliated Hospital of Zhejiang University School of Medicine.

Professor Wu Yilong at the Ivitinib ASCO Annual Conference Exhibition Area

Among more than 200 subjects treated with the recommended dose of avitinib (300mg BID), 90% of target lesions were clearly reduced, the objective tumor response rate (ORR) was 52.2%, the disease control rate (DCR) was 88.0%, and the Kaplan-Meier estimated median duration of disease response (DOR) was 7.64 months. Safety data show that the adverse events reported by subjects treated with avitinib were mainly grade 1 or 2, and there were no drug-related grade 5 adverse events. The main adverse events were similar to those of EGFR-TKIs that have been approved for marketing. The results of this clinical study show that subjects receiving avitinib treatment have clear efficacy, safety and good tolerance.